2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy

J Li; LS Lindstrom; JN Foo; S Rafiq; Marjanka K Schmidt; PDP Pharoah; K Michailidou; J Dennis; MK Bolla; Q (Qing) Wang; LJ (Laura) van 't Veer; S Cornelissen; E Rutgers; MC Southey; C Apicella; GS Dite; JL Hopper; PA Fasching; L Haeberle; AB Ekici; MW Beckmann; C Blomqvist; TA Muranen; K Aittomaeki; A Lindblom; S Margolin; A Mannermaa; VM Kosma; JM Hartikainen; V Kataja; G Chenevix-Trench; KA Phillips; SA McLachlan; D Lambrechts; B Thienpont; A Smeets; H Wildiers; J Chang-Claude; D Flesch-Janys; P Seibold; A Rudolph; GG Giles; L Baglietto; G Severi; CA Haiman; BE Henderson; F Schumacher; L Le Marchand; V Kristensen; GIG Alnaes; AL Borresen-Dale; S Nord; R Winqvist; K Pylkas; A Jukkola-Vuorinen; M Grip; IL Andrulis; JA Knight; G Glendon; S Tchatchou; P Devilee; R Tollenaar; Caroline Seynaeve; Maartje Hooning; Mieke Kriege; Antoinette Hollestelle; Ans van den Ouweland; Y Li; U Hamann; D Torres; HU Ulmer; T Rudiger; CY Shen; CN Hsiung; PE Wu; ST Chen; SH Teo; NAM Taib; CH Yip; GF Ho; K Matsuo; H Ito; H Iwata; K Tajima; D Kang; JY Choi; SK Park; KY Yoo; T Maishman; WJ Tapper; A Dunning; M Shah; R Luben; J Brown; CC Khor; DM Eccles; H Nevanlinna; D Easton; K Humphreys; J Liu; P Hall; K Czene

doi:10.1038/ncomms5051

2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy

J Li, LS Lindstrom, JN Foo, S Rafiq, Marjanka K Schmidt, PDP Pharoah, K Michailidou, J Dennis, MK Bolla, Q (Qing) Wang, LJ (Laura) van 't Veer, S Cornelissen, E Rutgers, MC Southey, C Apicella, GS Dite, JL Hopper, PA Fasching, L Haeberle, AB EkiciMW Beckmann, C Blomqvist, TA Muranen, K Aittomaeki, A Lindblom, S Margolin, A Mannermaa, VM Kosma, JM Hartikainen, V Kataja, G Chenevix-Trench, KA Phillips, SA McLachlan, D Lambrechts, B Thienpont, A Smeets, H Wildiers, J Chang-Claude, D Flesch-Janys, P Seibold, A Rudolph, GG Giles, L Baglietto, G Severi, CA Haiman, BE Henderson, F Schumacher, L Le Marchand, V Kristensen, GIG Alnaes, AL Borresen-Dale, S Nord, R Winqvist, K Pylkas, A Jukkola-Vuorinen, M Grip, IL Andrulis, JA Knight, G Glendon, S Tchatchou, P Devilee, R Tollenaar, Caroline Seynaeve, Maartje Hooning, Mieke Kriege, Antoinette Hollestelle, Ans van den Ouweland, Y Li, U Hamann, D Torres, HU Ulmer, T Rudiger, CY Shen, CN Hsiung, PE Wu, ST Chen, SH Teo, NAM Taib, CH Yip, GF Ho, K Matsuo, H Ito, H Iwata, K Tajima, D Kang, JY Choi, SK Park, KY Yoo, T Maishman, WJ Tapper, A Dunning, M Shah, R Luben, J Brown, CC Khor, DM Eccles, H Nevanlinna, D Easton, K Humphreys, J Liu, P Hall, K Czene

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)

16 Downloads (Pure)

Abstract

Large population-based registry studies have shown that breast cancer prognosis is inherited. Here we analyse single-nucleotide polymorphisms (SNPs) of genes implicated in human immunology and inflammation as candidates for prognostic markers of breast cancer survival involving 1,804 oestrogen receptor (ER)-negative patients treated with chemotherapy (279 events) from 14 European studies in a prior large-scale genotyping experiment, which is part of the Collaborative Oncological Gene-environment Study (COGS) initiative. We carry out replication using Asian COGS samples (n = 522, 53 events) and the Prospective Study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) study (n = 315, 108 events). Rs4458204_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n 2,641, 440 events, combined allelic hazard ratio (HR) = 1.81 (1.49-2.19); P for trend = 1.90 x 10(-9)). Such survival-associated variants can represent ideal targets for tailored therapeutics, and may also enhance our current prognostic prediction capabilities.

Original language	Undefined/Unknown
Journal	Nature Communications
Volume	5
DOIs	https://doi.org/10.1038/ncomms5051
Publication status	Published - 2014

Research programs

EMC MGC-02-96-01
EMC MM-03-86-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/ncomms5051

REPUB_54875_OA.pdfFinal published version, 849 KB

http://hdl.handle.net/1765/54875

Cite this

Li, J., Lindstrom, LS., Foo, JN., Rafiq, S., Schmidt, M. K., Pharoah, PDP., Michailidou, K., Dennis, J., Bolla, MK., Wang, Q., van 't Veer, LJ., Cornelissen, S., Rutgers, E., Southey, MC., Apicella, C., Dite, GS., Hopper, JL., Fasching, PA., Haeberle, L., ... Czene, K. (2014). 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 5. https://doi.org/10.1038/ncomms5051

@article{325204c1dbe94ea68f45ff2a87090a0a,

title = "2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy",

abstract = "Large population-based registry studies have shown that breast cancer prognosis is inherited. Here we analyse single-nucleotide polymorphisms (SNPs) of genes implicated in human immunology and inflammation as candidates for prognostic markers of breast cancer survival involving 1,804 oestrogen receptor (ER)-negative patients treated with chemotherapy (279 events) from 14 European studies in a prior large-scale genotyping experiment, which is part of the Collaborative Oncological Gene-environment Study (COGS) initiative. We carry out replication using Asian COGS samples (n = 522, 53 events) and the Prospective Study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) study (n = 315, 108 events). Rs4458204\_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n 2,641, 440 events, combined allelic hazard ratio (HR) = 1.81 (1.49-2.19); P for trend = 1.90 x 10(-9)). Such survival-associated variants can represent ideal targets for tailored therapeutics, and may also enhance our current prognostic prediction capabilities.",

author = "J Li and LS Lindstrom and JN Foo and S Rafiq and Schmidt, \{Marjanka K\} and PDP Pharoah and K Michailidou and J Dennis and MK Bolla and Wang, \{Q (Qing)\} and \{van 't Veer\}, \{LJ (Laura)\} and S Cornelissen and E Rutgers and MC Southey and C Apicella and GS Dite and JL Hopper and PA Fasching and L Haeberle and AB Ekici and MW Beckmann and C Blomqvist and TA Muranen and K Aittomaeki and A Lindblom and S Margolin and A Mannermaa and VM Kosma and JM Hartikainen and V Kataja and G Chenevix-Trench and KA Phillips and SA McLachlan and D Lambrechts and B Thienpont and A Smeets and H Wildiers and J Chang-Claude and D Flesch-Janys and P Seibold and A Rudolph and GG Giles and L Baglietto and G Severi and CA Haiman and BE Henderson and F Schumacher and \{Le Marchand\}, L and V Kristensen and GIG Alnaes and AL Borresen-Dale and S Nord and R Winqvist and K Pylkas and A Jukkola-Vuorinen and M Grip and IL Andrulis and JA Knight and G Glendon and S Tchatchou and P Devilee and R Tollenaar and Caroline Seynaeve and Maartje Hooning and Mieke Kriege and Antoinette Hollestelle and \{van den Ouweland\}, Ans and Y Li and U Hamann and D Torres and HU Ulmer and T Rudiger and CY Shen and CN Hsiung and PE Wu and ST Chen and SH Teo and NAM Taib and CH Yip and GF Ho and K Matsuo and H Ito and H Iwata and K Tajima and D Kang and JY Choi and SK Park and KY Yoo and T Maishman and WJ Tapper and A Dunning and M Shah and R Luben and J Brown and CC Khor and DM Eccles and H Nevanlinna and D Easton and K Humphreys and J Liu and P Hall and K Czene",

year = "2014",

doi = "10.1038/ncomms5051",

language = "Undefined/Unknown",

volume = "5",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

}

Li, J, Lindstrom, LS, Foo, JN, Rafiq, S, Schmidt, MK, Pharoah, PDP, Michailidou, K, Dennis, J, Bolla, MK, Wang, Q, van 't Veer, LJ, Cornelissen, S, Rutgers, E, Southey, MC, Apicella, C, Dite, GS, Hopper, JL, Fasching, PA, Haeberle, L, Ekici, AB, Beckmann, MW, Blomqvist, C, Muranen, TA, Aittomaeki, K, Lindblom, A, Margolin, S, Mannermaa, A, Kosma, VM, Hartikainen, JM, Kataja, V, Chenevix-Trench, G, Phillips, KA, McLachlan, SA, Lambrechts, D, Thienpont, B, Smeets, A, Wildiers, H, Chang-Claude, J, Flesch-Janys, D, Seibold, P, Rudolph, A, Giles, GG, Baglietto, L, Severi, G, Haiman, CA, Henderson, BE, Schumacher, F, Le Marchand, L, Kristensen, V, Alnaes, GIG, Borresen-Dale, AL, Nord, S, Winqvist, R, Pylkas, K, Jukkola-Vuorinen, A, Grip, M, Andrulis, IL, Knight, JA, Glendon, G, Tchatchou, S, Devilee, P, Tollenaar, R, Seynaeve, C, Hooning, M, Kriege, M, Hollestelle, A, van den Ouweland, A, Li, Y, Hamann, U, Torres, D, Ulmer, HU, Rudiger, T, Shen, CY, Hsiung, CN, Wu, PE, Chen, ST, Teo, SH, Taib, NAM, Yip, CH, Ho, GF, Matsuo, K, Ito, H, Iwata, H, Tajima, K, Kang, D, Choi, JY, Park, SK, Yoo, KY, Maishman, T, Tapper, WJ, Dunning, A, Shah, M, Luben, R, Brown, J, Khor, CC, Eccles, DM, Nevanlinna, H, Easton, D, Humphreys, K, Liu, J, Hall, P & Czene, K 2014, '2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy', Nature Communications, vol. 5. https://doi.org/10.1038/ncomms5051

TY - JOUR

T1 - 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy

AU - Li, J

AU - Lindstrom, LS

AU - Foo, JN

AU - Rafiq, S

AU - Schmidt, Marjanka K

AU - Pharoah, PDP

AU - Michailidou, K

AU - Dennis, J

AU - Bolla, MK

AU - Wang, Q (Qing)

AU - van 't Veer, LJ (Laura)

AU - Cornelissen, S

AU - Rutgers, E

AU - Southey, MC

AU - Apicella, C

AU - Dite, GS

AU - Hopper, JL

AU - Fasching, PA

AU - Haeberle, L

AU - Ekici, AB

AU - Beckmann, MW

AU - Blomqvist, C

AU - Muranen, TA

AU - Aittomaeki, K

AU - Lindblom, A

AU - Margolin, S

AU - Mannermaa, A

AU - Kosma, VM

AU - Hartikainen, JM

AU - Kataja, V

AU - Chenevix-Trench, G

AU - Phillips, KA

AU - McLachlan, SA

AU - Lambrechts, D

AU - Thienpont, B

AU - Smeets, A

AU - Wildiers, H

AU - Chang-Claude, J

AU - Flesch-Janys, D

AU - Seibold, P

AU - Rudolph, A

AU - Giles, GG

AU - Baglietto, L

AU - Severi, G

AU - Haiman, CA

AU - Henderson, BE

AU - Schumacher, F

AU - Le Marchand, L

AU - Kristensen, V

AU - Alnaes, GIG

AU - Borresen-Dale, AL

AU - Nord, S

AU - Winqvist, R

AU - Pylkas, K

AU - Jukkola-Vuorinen, A

AU - Grip, M

AU - Andrulis, IL

AU - Knight, JA

AU - Glendon, G

AU - Tchatchou, S

AU - Devilee, P

AU - Tollenaar, R

AU - Seynaeve, Caroline

AU - Hooning, Maartje

AU - Kriege, Mieke

AU - Hollestelle, Antoinette

AU - van den Ouweland, Ans

AU - Li, Y

AU - Hamann, U

AU - Torres, D

AU - Ulmer, HU

AU - Rudiger, T

AU - Shen, CY

AU - Hsiung, CN

AU - Wu, PE

AU - Chen, ST

AU - Teo, SH

AU - Taib, NAM

AU - Yip, CH

AU - Ho, GF

AU - Matsuo, K

AU - Ito, H

AU - Iwata, H

AU - Tajima, K

AU - Kang, D

AU - Choi, JY

AU - Park, SK

AU - Yoo, KY

AU - Maishman, T

AU - Tapper, WJ

AU - Dunning, A

AU - Shah, M

AU - Luben, R

AU - Brown, J

AU - Khor, CC

AU - Eccles, DM

AU - Nevanlinna, H

AU - Easton, D

AU - Humphreys, K

AU - Liu, J

AU - Hall, P

AU - Czene, K

PY - 2014

Y1 - 2014

N2 - Large population-based registry studies have shown that breast cancer prognosis is inherited. Here we analyse single-nucleotide polymorphisms (SNPs) of genes implicated in human immunology and inflammation as candidates for prognostic markers of breast cancer survival involving 1,804 oestrogen receptor (ER)-negative patients treated with chemotherapy (279 events) from 14 European studies in a prior large-scale genotyping experiment, which is part of the Collaborative Oncological Gene-environment Study (COGS) initiative. We carry out replication using Asian COGS samples (n = 522, 53 events) and the Prospective Study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) study (n = 315, 108 events). Rs4458204_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n 2,641, 440 events, combined allelic hazard ratio (HR) = 1.81 (1.49-2.19); P for trend = 1.90 x 10(-9)). Such survival-associated variants can represent ideal targets for tailored therapeutics, and may also enhance our current prognostic prediction capabilities.

AB - Large population-based registry studies have shown that breast cancer prognosis is inherited. Here we analyse single-nucleotide polymorphisms (SNPs) of genes implicated in human immunology and inflammation as candidates for prognostic markers of breast cancer survival involving 1,804 oestrogen receptor (ER)-negative patients treated with chemotherapy (279 events) from 14 European studies in a prior large-scale genotyping experiment, which is part of the Collaborative Oncological Gene-environment Study (COGS) initiative. We carry out replication using Asian COGS samples (n = 522, 53 events) and the Prospective Study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) study (n = 315, 108 events). Rs4458204_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n 2,641, 440 events, combined allelic hazard ratio (HR) = 1.81 (1.49-2.19); P for trend = 1.90 x 10(-9)). Such survival-associated variants can represent ideal targets for tailored therapeutics, and may also enhance our current prognostic prediction capabilities.

U2 - 10.1038/ncomms5051

DO - 10.1038/ncomms5051

M3 - Article

C2 - 24937182

SN - 2041-1723

VL - 5

JO - Nature Communications

JF - Nature Communications

ER -